Characterization of six clinical drugs and dietary intervention in the nonobese CDAA-HFD mouse model of MASH and progressive fibrosis
Malte Hasle Nielsen, Jacob Nøhr-Meldgaard, Mathias B. Møllerhøj, Denise Oró, Susanne Elisabeth Pors, M Andersen, Ioannis Kamzolas, Evangelia Petsalaki, Michèle Vacca, Lea Mørch Harder, James W. Perfield, Sanne Skovgård Veidal, Henrik H. Hansen, Michael Feigh
Abstract
The CDAA-HFD mouse model is widely used in preclinical MASH research, but validation of the model is lacking. This study presents the longitudinal characterization of disease progression. Furthermore, late-stage clinical compounds and dietary intervention (chow reversal) display distinct hepatoprotective effects in the model. Collectively, the study provides critical information guiding the use of the CDAA-HFD mouse model in preclinical drug discovery for MASH and fibrosis.
Topics & Concepts
MedicineFibrosisSteatosisSteatohepatitisInternal medicineSemaglutideEndocrinologyDiseaseDiabetes mellitusFatty liverType 2 diabetesLiraglutideLiver Disease Diagnosis and TreatmentHepatocellular Carcinoma Treatment and PrognosisCholangiocarcinoma and Gallbladder Cancer Studies